ASX:CYC (Australia)  
Cyclopharm Ltd logo

Cyclopharm Ltd

A$ 1.35 (+3.05%) Sep 29
P/E:
At Loss
P/B:
3.01
Market Cap:
A$ 122.32M ($ 79.39M)
Enterprise V:
A$ 100.23M ($ 65.05M)
Volume:
10.70K
Avg Vol (2M):
12.99K
Volume:
10.70K
Market Cap A$:
122.32M
Market Cap $:
79.39M
PE Ratio:
At Loss
Avg Vol (2-Month):
12.99K
Enterprise Value A$:
100.23M
Enterprise Value $:
65.05M
PB Ratio:
3.01
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
Name Current Vs Industry Vs History
Cash-To-Debt 6
Equity-to-Asset 0.77
Debt-to-Equity 0.11
Debt-to-EBITDA -2.28
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.41
Distress
Grey
Safe
Beneish M-Score -3.06
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 42.5
9-Day RSI 37.9
14-Day RSI 39.86
6-1 Month Momentum % -11.59
12-1 Month Momentum % -12.12

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.53
Quick Ratio 4.75
Cash Ratio 3.71
Days Inventory 308.79
Days Sales Outstanding 97.72
Days Payable 201.76

Dividend & Buy Back

Name Current Vs Industry Vs History
Dividend Yield % 0.76
Forward Dividend Yield % 0.76
5-Year Yield-on-Cost % 0.77
3-Year Average Share Buyback Ratio -10.8

Financials

ASX:CYC's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$) 20.779
EPS (TTM) (A$) -0.04
Beta 0.55
Volatility % 60.06
14-Day RSI 39.86
14-Day ATR (A$) 0.041394
20-Day SMA (A$) 1.433
12-1 Month Momentum % -12.12
52-Week Range (A$) 0.95 - 2.14
Shares Outstanding (Mil) 93.37

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cyclopharm Ltd Filings

Document Form Filing Date
No Filing Data

Cyclopharm Ltd Analysis

Share your research